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A significant proportion of patients with severe mitral regurgitation (MR) do not undergo 
surgical repair or replacement due to age, comorbidities or severe left ventricular (LV) 
dysfunction. Furthermore, benefits from surgery in these high-risk patients are uncertain.1-3) 
Transcatheter mitral valve repair has emerged as an established treatment option for high 
surgical risk patients with severe MR. Among them, MitraClip (Abbott Vascular, Santa Clara, 
CA, USA) is the major commercially available technology using the edge-to edge technique for 
valve repair and has achieved both Food and Drug Administration (FDA) and CE Mark approval.
Lee et al.4) reported the results of 46 patients with severe MR who underwent MitraClip in 
a single center. In this retrospective study, the authors demonstrated that all the patients, 
regardless of age, benefited from significant improvement in New York Heart Association 
(NYHA) functional class and 6-minute walk test. Moreover, overall 1-year survival rate 
was comparable in older age group compared to younger aged group. As data involving 
transcatheter mitral valve repair in the Asian population are scarce,5) the fact that MitraClip 
showed favorable results in the Asian population and that such results are consistent with 
previous studies involving western population could be meaningful.
However, the results of the current study should be cautiously interpreted. As the author 
already mentioned as a limitation, there was a significant difference in MR etiology. The 
proportion of degenerative MR was significantly higher in older patients while functional 
MR was predominant in younger patients. As secondary or functional MR is developed due 
to leaflet tethering and mitral annular dilatation caused by LV remodeling from ischemic or 
non-ischemic cardiomyopathy, it is closely related to poor prognosis especially in patients 
with decreased LV systolic function. Although LV ejection fraction and other baseline 
characteristics were adjusted by multiple logistic regression, the effect of age on all cause 
death could still be attenuated especially in a study with a small number of patients.
Regarding the indication of transcatheter mitral valve repair, both American Heart 
Association/American College of Cardiology (AHA/ACC) and European Society of Cardiology/
European Association of Cardiovascular Surgery (ESC/EACTS) guidelines recommended 
that in patients with primary or degenerative MR who have a prohibitive surgical risk, 
transcatheter mitral valve repair may be considered (class IIb, level of evidence B in AHA/
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► See the article “Can Elderly Patients with Severe Mitral Regurgitation Benefit from Trans-catheter 
Mitral Valve Repair?” in volume 49 on page 532.
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ACC guideline, and class IIb, level of evidence C in ESC/EACTS guideline).6)7) However, 
in the case of secondary or functional MR, the effect of transcatheter mitral valve repair 
on clinical outcome needs to be further investigated. Recently, 2 randomized controlled 
trials, Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients 
With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes 
Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional 
Mitral Regurgitation (COAPT), showed discrepant results on efficacy of MitraClip in patients 
with heart failure and functional MR.8)9) It suggests that, in patients with functional MR, 
further study would be needed regarding the appropriate indication of MitraClip to achieve 
additional clinical benefit beyond conventional treatment.
Since the Endovascular Valve Edge-to-Edge Repair Study (EVEREST II) trial first introduced,10) 
several studies provide growing evidence of long term efficacy and safety in patients with 
transcatheter mitral valve repair. Among them, Kar et al.11) demonstrated long term safety 
and efficacy of MitraClip in high surgical risk patients which showed durable improvement 
NYHA class in surviving patients. In the study, the observed mortality was most likely a 
consequence of the advanced age and comorbidity.
In aged patients, not only progression of cardiovascular disease, but also the risk of open 
heart surgery increase and transcatheter mitral valve repair may satisfy these unmet needs. 
To accurately predict the potential benefit of transcatheter mitral valve repair compared to 
surgery or medical treatment and to achieve the benefit and avoid futility, clarification of MR 
etiology and careful interpretation would be indispensable.
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